180 Life Sciences Corp. (ATNF) News

180 Life Sciences Corp. (ATNF): $0.87

0.02 (+2.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATNF to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter ATNF News Items

ATNF News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ATNF News From Around the Web

Below are the latest news stories about 180 Life Sciences Corp that investors may wish to consider to help them evaluate ATNF as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today.

William White on InvestorPlace | April 4, 2022

180 Life Sciences Corp. Forms Scientific Advisory Board

PALO ALTO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the formation of a scientific advisory board (SAB). Dr. Jonathan Rothbard, 180 Life Sciences Chief Scientific Officer stated, “We are pleased to announce the formation of the scientific advisory board

Yahoo | February 17, 2022

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

PALO ALTO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to shareholders from its Chief Executive Officer, Dr. James Woody. Dear Fellow Shareholders, As you may recall, I previously authored a letter to you at the end of August 2021. I con

Yahoo | January 31, 2022

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. Dr. James Woody, President & Chief Executive Officer, will present an overview of 180 L

Yahoo | December 28, 2021

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu Buys 8,000 Shares

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu acquired 8,000 shares of the companys stock in a transaction dated Thursday, December 16th. The shares were bought at an average cost of $3.98 per share, with a total value of $31,840.00. The acquisition was disclosed in a document filed with the SEC, which is accessible []

Transcript Daily | December 16, 2021

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (Oxford) for the development and commercialization of HMGB1, a regenerative molecule for promoting liver repair and regeneration. Under the terms of the transaction, the Company will pay Oxford a small one-time upfront license fee, which will have an insignificant impact on the 2022 expenditure rate; and any further payments are contingent upon the achievement of certain clinical, regulatory and sale...

Intrado Digital Media | December 15, 2021

Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares

Investors who take an interest in 180 Life Sciences Corp. ( NASDAQ:ATNF ) should definitely note that the Lead...

Yahoo | December 12, 2021

180 Life Sciences Corp. (NASDAQ:ATNF) CEO James N. Woody Acquires 12,500 Shares

180 Life Sciences Corp. (NASDAQ:ATNF) CEO James N. Woody purchased 12,500 shares of the firms stock in a transaction dated Thursday, December 9th. The stock was acquired at an average price of $4.27 per share, with a total value of $53,375.00. The acquisition was disclosed in a filing with the SEC, which can be accessed []

Transcript Daily | December 11, 2021

Quan Anh Vu Purchases 4,500 Shares of 180 Life Sciences Corp. (NASDAQ:ATNF) Stock

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu bought 4,500 shares of the firms stock in a transaction that occurred on Friday, December 10th. The stock was bought at an average price of $3.90 per share, for a total transaction of $17,550.00. The transaction was disclosed in a legal filing with the Securities & []

Dakota Financial News | December 10, 2021

180 Life Sciences Corp. (NASDAQ:ATNF) Director Jr. Donald A. Mcgovern Acquires 25,000 Shares

180 Life Sciences Corp. (NASDAQ:ATNF) Director Jr. Donald A. Mcgovern bought 25,000 shares of the businesss stock in a transaction dated Thursday, December 9th. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $103,250.00. The purchase was disclosed in a filing with the SEC, which is accessible []

Dakota Financial News | December 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5843 seconds.